BiondVax universal flu vaccine patent application accepted in Australia

BiondVax universal flu vaccine patent application accepted in Australia

April 15, 2019 Off By Dino Mustafić

BiondVax Pharmaceuticals got its patent application covering formulation and production processes of the M-001 universal influenza vaccine candidate accepted in Australia.

In the announcement the company said that the application titled “Compositions of multimeric-multiepitope influenza polypeptides and their production” has been filed in eight other jurisdictions, and is under examination in Europe, China, Japan, and the USA.

Dr. Tamar Ben-Yedidia, BiondVax’s Chief Science Officer, was referred to ass aying in the release, “Our five patent families cover multimeric-multiepitope polypeptides as well as composition, use, formulation and production aspects of M-001, BiondVax’s Phase 3 universal flu vaccine candidate. We are pleased the Australian authorities have accepted this patent, which widens and strengthens our international IP portfolio.

BiondVax is currently conducting a pivotal, clinical efficacy, Phase 3 trial of M-001 in Europe. 4,094 participants were recruited prior to the 2018/19 flu season, and preparations are proceeding as planned towards the trial’s second season of 2019/20, in which at least 6,000 participants are expected to be enrolled. The placebo-controlled trial will assess safety and effectiveness of M-001 alone in reducing flu illness and severity in adults aged 50 years and older. Results are expected by the end of 2020.